Ask the Experts: Low-cost AIDS Drugs 6/16/2004
Kaiser Family Foundation Broadcast Studio, Washington, D.C.
View Webcast
( video
)
(
transcript )
Millions of people living with HIV/AIDS around the world have no access to antiretroviral therapy to treat HIV or stave off its development. Lower-cost drugs, including generics, would stretch existing resources further, though debate continues over their distribution. The World Health Organization uses a pre-qualification process with standards for safety and efficacy. The U.S. has just announced plans for a new fast-track review program by the Food and Drug Administration to speed the global delivery of less expensive medications, including generic and brand name fixed dose combinations.
During this webcast,
Mark Dybul, M.D., deputy chief medical officer,
Office of the U.S. Global AIDS Coordinator;
David Hoos,
M.D., M.P.H., assistant professor,
Columbia University Mailman School of Public Health; and
Jen Kates, M.A., M.P.A., director, HIV Policy,
Kaiser Family Foundation discussed low-cost AIDS drugs.
kaisernetwork.org's Editor-in-Chief and Kaiser Family Foundation Vice President Larry Levitt hosted.
Access previous Ask the Experts shows here.
Sign up for
email alerts and stay informed about upcoming HealthCasts, and the latest health policy issues, news, and events.
Change Your Video Preferences
